SUPRAX 400 MG
CEFIXIME : 400 MG · DIN 02195984 · AVENTIS PHARMA INC
Health Canada status: CANCELLED POST MARKET
What is SUPRAX?
SUPRAX 400 MG contains CEFIXIME : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02195984, held by AVENTIS PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 16-Jan-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02195984 |
|---|---|
| Brand name | SUPRAX |
| Generic / active ingredient | CEFIXIME : 400 MG |
| Manufacturer | AVENTIS PHARMA INC |
| Strength | 400 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01DD08 CEFIXIME |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 16-Jan-2006 |
What can be used instead?
Other Canadian products sharing ATC code J01DD08 CEFIXIME. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-CEFIXIME | 100 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | DIN 02468689 |
| AURO-CEFIXIME | 400 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02432773 |
| SUPRAX | 100 MG / 5 ML | POWDER FOR SUSPENSION | ODAN LABORATORIES LTD | MARKETED | DIN 00868965 |
| SUPRAX | 400 MG | TABLET | ODAN LABORATORIES LTD | MARKETED | DIN 00868981 |
| SUPRAX | 100 MG / 5 ML | POWDER FOR SOLUTION | AVENTIS PHARMA INC | CANCELLED POST MARKET | DIN 02195992 |
| SUPRAX | 200 MG | TABLET | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | DIN 00868973 |
| SUPRAX - TAB 200MG | 200 MG | TABLET | RHONE-POULENC RORER CANADA INC. | CANCELLED POST MARKET | DIN 02195976 |
Who else supplies CEFIXIME worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFIXIME appears in 4714 registered pack listings across 8 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.